Positive update on the development of new XF‐platform drug formulations24 Mar 2020
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.
Destiny Pharma, a clinical-stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), has completed the initial phase of its project to develop new topical formulations of the former’s novel XF‐platform drugs.
Further to forming the collaboration with MedPharm — a contract provider of topical and transdermal product design and formulation development services — last year, the project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections.
These formulations will form the basis of XF drug delivery for Destiny Pharma’s preclinical and clinical programmes and treatments for both acute and chronic infections.
Selected formulations will also be incorporated into ongoing grant-funded projects including Destiny Pharma's UK-China AMR, Innovate UK grant-funded collaboration.
"There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance. Our lead drug candidate from the XF-platform, XF‐73 nasal gel, for the prevention of post‐surgical infections, is currently in Phase IIb development with data expected in mid-2020,” said Neil Clark, CEO of Destiny Pharma.
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment
25 May 2020
The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.Read more
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation